Lack of prognostic relevance of Her-2/neu, topoisomerase IIα and EGFR in advanced ovarian carcinoma

Author：

ISSN： 1792-0981

Source： Experimental and Therapeutic Medicine, Vol.3, Iss.5, 2012-01, pp. : 828-834

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Her-2/ neu and Topoisomerase iiα in Breast Cancer

By Järvinen T.A.H.

Breast Cancer Research and Treatment, Vol. 78, Iss. 3, 2003-04 ,pp. : 299-311

Springer Publishing Company

Access to resources Recommend Favorite

Analyzing Toposimerase II-α and HER-2/neu co-amplification seems to be of limited value in epithelial ovarian cancer

By Maenpaa Johanna Tanner Minna Isola Jorma

Acta Oncologica, Vol. 48, Iss. 4, 2009-05 ,pp. : 617-619

Informa Healthcare

Access to resources Recommend Favorite

Cyclooxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian Cancer

By Ferrandina G. Ranelletti F.O. Lauriola L. Fanfani F. Legge F. Mottolese M. Nicotra M.R. Natali P.G. Zakut V.H. Scambia G.

Gynecologic Oncology, Vol. 85, Iss. 2, 2002-05 ,pp. : 305-310

Academic Press

Access to resources Recommend Favorite

Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma

By Bermont L.

Breast Cancer Research and Treatment, Vol. 63, Iss. 2, 2000-09 ,pp. : 163-169

Springer Publishing Company

Access to resources Recommend Favorite

Different detection rates of HER-2/NEU overexpression in ovarian carcinoma using two different commercially available detection kits

By Romero H. Schneider J.

European Journal of Cancer, Vol. 31, Iss. 6, 1995-06 ,pp. : 1020-1021

Elsevier

Access to resources Recommend Favorite